With ketamine safety, the context matters: the intended use, patient screening, route of administration, dose, setting, and medical monitoring all play a critical role in shaping risk.
Ketamine’s primary safety risks occur when it is used recreationally versus when used in a safe, medically monitored environment.
Medical IV Ketamine at Ember
Physician-Directed Care
✓
Intended to treat depression
✓
FDA-approved, regulated, pharmaceutical-grade medication
✓
Physician-directed, precise, low-dosing
✓
Administered in a medical environment
✓
Continuous 1:1 clinical monitoring
✓
Carefully screened patients
✓
Emergency equipment on hand
Recreational Ketamine
Unsupervised Use
✗
Often intended to produce an altered state
✗
Source may be unknown, often mixed with other substances
✗
Uncontrolled dosing, often very high
✗
Often taken in uncontrolled settings
✗
No medical monitoring
✗
No medical screening
✗
No immediate medical support
While the molecule may be the same, the context in which ketamine is used fundamentally changes its purpose, safety profile, and risks.

A Tale of Two Ketamines: Addressing the Headlines Around Elon Musk

Mourning The Vivienne: Defining Abuse vs. Therapeutic Use of Ketamine

Matthew Perry: with ketamine, the details matter

Misuse to Medicine: Reclaiming Healing Ketamine from the Diddy Headlines
Intravenously (IV) at Ember
Oral / Lozenge
Intranasal
Intramuscular (IM)
Drug Source
FDA-approved generic medication
Compounded, current FDA warning
Compounded, current FDA warning
FDA-approved generic medication
Bioavailability
100%
~20%
~40%
~90%
Dose Ranges
~40 – 50 mg
~200 – 1,200 mg
~80 – 200 mg
~50 – 60 mg
Session Duration
40 – 60 minutes, can be stopped anytime, metabolized quickly (in minutes)
2 – 4 hours, cannot be stopped once ingested
1 – 2 hours, cannot be stopped once sprayed
1 – 2 hours, cannot be stopped once injected
Monitoring
1:1 by trained clinician
Often at-home or with sitter lacking clinical training in safety
Varies from clinic to clinic
Varies from clinic to clinic
Dose Frequency
Average of once every 6 weeks (ranges 2 – 10 weeks)
Often weekly or multiple times a week
Often weekly or multiple times a week
Weekly or every ~2 weeks
Outcomes
~84%
~20%
~40%
~50%
| Intravenous (IV) at Ember | Oral / Lozenge | Intranasal | Intramuscular (IM) | |
|---|---|---|---|---|
| Drug Source | FDA-approved generic medication | Compounded, current FDA warning | Compounded, current FDA warning | FDA-approved generic medication |
| Bioavailability | 100% | ~30% | ~40% | ~90% |
| Dose Ranges | ~40 - 50 mg | ~200 - 1,200 mg | ~80 - 200 mg | ~50 - 60 mg |
| Session Duration | 40 - 60 minutes, can be stopped anytime, metabolized quickly (in minutes) | 2 - 4 hours, cannot be stopped once ingested | 1 - 2 hours, cannot be stopped once sprayed | 1 - 2 hours, cannot be stopped once injected |
| Monitoring | 1:1 by trained clinician | Often at-home or with sitter lacking clinical training in safety | Varies from clinic to clinic | Varies from clinic to clinic |
| Dose Frequency | Average of once every 6 weeks (ranges 2–10 weeks) | Often weekly or multiple times a week | Often weekly or multiple times a week | Weekly or every ~2 weeks |
| Outcomes | ~84% | ~20% | ~30% | ~50% |
Intravenous (IV) ketamine infusions and intramuscular (IM) injections use FDA-approved generic racemic ketamine, manufactured and distributed by authorized producers and distributors that ensure quality control and substance purity.
Intranasal and oral ketamine (lozenges, troches) require modification before use, and are made by compounding pharmacies that may lack substance-safety oversight and have been warned against by the FDA.
A medication’s side-effect profile relates to the total amount consumed, as all of it is processed by the kidney and liver. IV ketamine enters the bloodstream directly, so 100% goes where it is needed, leading to the lowest dose for benefit. Oral ketamine is only ~30% bioavailable, with average doses ~3–10× greater than IV increasing the potential side effects.
IV ketamine is 100% bioavailable (meaning it is completely absorbed into the bloodstream) and therefore uses a small, precise dose — roughly 40 – 50 mg for most patients. Other routes absorb less efficiently, and have to make up the difference with far larger amounts: oral and lozenge doses commonly run ~200 – 1,200 mg, and intranasal ~80 – 200 mg. Because those routes are absorbed through other tissues, rather than delivered straight to the bloodstream, actual medication absorption varies from person to person, resulting in larger, less predictable dosing and increased risk of side effects.
An IV infusion can be stopped at any time, and the medication clears from the system within minutes. Oral, intranasal, and intramuscular ketamine cannot be stopped once ingested or injected — so someone having an adverse reaction cannot halt it, and effects may continue for multiple hours.
IV ketamine infusions at Ember are continuously monitored by a medical clinician trained to ensure clinical and psychological safety. Oral and intranasal sessions are often unmonitored in a home environment, or monitored by guides or therapists who are not medically licensed for clinical safety.
IV ketamine at Ember requires single booster infusions on average of once every 6 weeks to maintain the benefits established in the foundation of care (4 infusions over 2 weeks). Oral and intranasal ketamine are often taken weekly or multiple times a week — higher doses, more frequently — placing higher cumulative load on the brain and body.
Of all the ways ketamine can be administered for depression, intravenous (IV) delivery is the most studied, with the highest efficacy rate and the best long-term outcomes. Because IV delivers the full dose directly and predictably at 100% bioavailability, clinicians can target the dosage window shown to maximize the treatment’s antidepressant potential. We also titrate each dose to the individual under our care, accounting for any potential medication interactions. At Ember, 84% of our patients experience meaningful relief from depression through IV ketamine treatment.
The FDA issued guidance in 2023 warning against the use of compounded ketamine (oral and intranasal ketamine), and stated that ketamine should only be accessed in medically supervised settings. The agency notes that serious complications — including breathing suppression, cardiovascular instability, and other emergencies — can occur and require rapid clinical intervention by a trained clinician.
The American Psychiatric Association (APA) consensus guidelines for IV ketamine treatment of depression require administration by trained licensed clinicians, facility capabilities to monitor cardiovascular and respiratory function, pre-treatment diagnostic and medical evaluations, and a formal informed consent process.
The American Society of Ketamine Physicians, Psychotherapists, & Practitioners (ASKP3) is the world’s largest professional society of ketamine clinicians. In June 2026, an interdisciplinary working group from ASKP3, including Ember Health co-founder Dr. Nico Grundmann, created Guidelines on the Use of IV Ketamine for Depressive Disorders, published in the Journal of Affective Disorders. While the full publication includes 73 consensus recommendations, several themes emerged with particularly strong agreement among experts:
1. Existing data supports IV ketamine for clinical depression.
2. All treatments should be monitored and delivered by medical professionals experienced in medical and psychological safety support.
3. Dosing should be kept within well-defined and studied ranges.
4. All care should be coordinated within a larger psychiatric care team.
Mild Adverse Events
Medically Serious Adverse Events (MSAE)
Common side effects that respond to intervention.
Occurrences that may or may not require stopping treatment.
Rare occurrences that require stopping treatment.
•
Nausea
•
Emesis (vomiting)
•
Anaphylaxis
•
Headache
•
Hypertension or Tachycardia
•
Seizure
•
Psychological Difficulty
•
…
•
Laryngospasm
•
…
•
…
•
Apnea or Hypoxia
1 in 1,000
A 2023 published review showed a 0.1% instance rate of medically serious adverse events (MSAE) in ketamine administration for mental health (source). At Ember, we’ve safely resolved MSAEs in the 1 in 1,600 infusions they have occurred under our care.
✓
Careful patient screening
✓
Collaboration with outside mental health providers
✓
Evidence-based, individualized dosing
✓
1:1 clinician presence throughout treatment
✓
Physician oversight
✓
Emergency preparedness
✓
Measurement-based long-term care planning
The best available research on serious medical adverse events in ketamine treatment was published in 2023. That study found that serious medical adverse events occur in about 0.1% of ketamine treatment sessions—approximately one in every 1,000 infusions.
VIEW THE PAPER →Ember Health conducted a large internal review of 32,018 infusions delivered to 2,174 unique patients. These findings were presented at The ASKP3 2026 Conference, and are being prepared for publication with collaborators at Harvard Medical School and Mass General Brigham.
VIEW THE ARTICLE →As part of our large internal review of over 30,000 infusions over 5.5 years of care in partnership with Harvard Medical School, Massachusetts General Brigham Hospital (MGB), we examined psychologically challenging experiences during ketamine treatment. The data shows that 90% of these sessions are successfully supported through verbal reassurance and therapeutic interventions by our team, without the need to stop the infusion or administer benzodiazepines.
A conversation between Dr. Owen Muir and Dr. Nico Grundmann about why ketamine resists easy categorization, what our clinical data reveals about patient safety, and the risks of treating supervision as optional.
READ THE INTERVIEW →Every treatment in medicine carries some risk, and IV ketamine is no exception. That said, IV ketamine in a monitored clinical setting carries a very strong safety profile. The best available research places serious medical events at roughly 1 in 1,000 infusions, and in our own review of over 40,000 infusions, the large majority of sessions passed calmly with no clinical intervention needed. The 0.1% serious adverse events were resolved without long term health consequence due to the training and preparedness of our team. These safety numbers are very specific to our doses, the IV route, the setting, patient screening, and who’s in our treatment rooms.
Almost all of the ketamine stories in the news describe recreational or unsupervised use — unknown sources, uncontrolled, often very high doses, no medical screening, and no one trained to respond if something goes wrong. Medical IV ketamine at Ember is fundamentally different: we use pharmaceutical-grade FDA-approved medications, precise dosing directed by a physician, carefully screen patients, and have a clinician present the entire time. Risk is determined by how the treatment is administered, not the substance itself.
The most common side effects of IV ketamine are nausea, headache, dizziness, a sense of dissociation, and fatigue. These are typically mild, happen during or shortly after the infusion, and resolve as the medication clears, usually within minutes of the infusion ending. From Ember Health’s data, about a quarter of patients report feeling some nausea, but only a small fraction ever need medication for it during the session itself.
Serious adverse events — things like a significant change in heart rate or blood pressure, or a breathing-related event — are rare. The published research puts them at about 0.1% of sessions, and our own review of more than 40,000 infusions found a comparable rate. In that entire dataset, no case required resuscitation equipment, and while a small number of patients were sent to the ER for evaluation after in-office care, every one resolved with no lasting harm. We track these events transparently precisely because being prepared for the rare case is what keeps treatment safe.
How ketamine enters your body changes how predictable and controllable it is. IV delivers 100% of the dose directly to the bloodstream, which allows for precise dosing and the ability to slow or stop the infusion and clear the medication within minutes. Oral, nasal, and intramuscular ketamine are absorbed less efficiently or predictably, require higher total doses, and can’t be stopped once taken. At-home and lozenge programs are often unmonitored or administered by people without clinical safety skills, changing the safety profile considerably.
At Ember, our care model is built around keeping people safe. That starts with careful patient screening conducted in partnership with licensed mental health providers. During treatment, a clinician is monitoring the entire session, with physician oversight and emergency equipment on site. Dosing is individualized rather than one-size-fits-all, and we coordinate care using ongoing mood measurement rather than guesswork. Every known side effect has a standard protocol behind it, so if something does come up, the response is immediate and practiced.
Ember Health works with patients managing Major Depressive Disorder and the depressive state of Bipolar Disorder. Certain medical or psychiatric histories may mean treatment should be deferred, approached differently, or that another option is a better fit. We provide a free consultation with a clinician from our team to assess fit and coordinate with the broader care team. If IV ketamine isn’t right for you, we’ll tell you.
This is one of the most common concerns, and it’s a fair one. Recreational use of ketamine often involves frequent, high-dose, self-directed administration without safety protocols, and can lead to addictive patterns and detrimental long term health impacts. When ketamine is administered in a structured, protocolized, medical environment like Ember, with precise dosing and infrequent exposure, it does not become addictive, and there is no evidence to suggest long-term harm. Research into ketamine’s long-term effects is ongoing, and we stay abreast of all emerging literature — which is part of why we favor the lowest effective dose and the most controlled route of delivery.
About 1 in 20 sessions is described by our patients as psychologically challenging. With that said, you won’t be alone – a clinician will be with you the entire session to ensure your clinical safety and provide psychological support. At Ember, 90% of all emotionally challenging sessions have been successfully supported without the need to stop the pump or administer benzodiazepine medications. These experiences usually pass with support, and many patients later describe them as a meaningful part of the process. If you’re feeling anxious going in, let your Ember clinician know, and they can provide the support you need to feel safe and secure.
Our Evidence page holds more information regarding ketamine data, our own safety research, FDA guidance, and more. Additionally, our blog is a great resource for supporting evidence. If you have a question you don’t see reflected in our information, please reach out to us directly.